A B7-H4–Targeting Antibody–Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression
Authors:
- Sarah B. GittoSGSarah B. Gitto
- Margaret WhickerMWMargaret Whicker
- Gareth DaviesGDGareth Davies
- Sushil KumarSKSushil Kumar
- Krista KinneerKKKrista Kinneer
- Haineng XuHXHaineng Xu
- Arthur LewisALArthur Lewis
- Srinivas MamidiSMSrinivas Mamidi
- Sergey MedvedevSMSergey Medvedev
- Hyoung KimHKHyoung Kim
- Judith AndertonJAJudith Anderton
- E. Jessica. TangETE. Jessica. Tang
- 26 October 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (8) , 1567-1581
Abstract
Purpose: Platinum and PARP inhibitors (PARPi) demonstrate activity in breast and ovarian cancers, but drug resistance ultimately emerges. Here, we examine B7-H4 expression in primary and recurrent high-grade serous ovarian carcinoma (HGSOC) and the activity of a B7-H4-directed antibody–drug conjugate (B7-H4-ADC), using a pyrrolobenzodiazepine-dimer payload, in PARPi- and platinum-resistant HGSOC patient-derived xenograft (PDX) models. Experimental Design: B7-H4 expression was quantified by flow cytometry and IHC. B7-H4-ADC efficacy was tested against multiple cell lines in vitro and PDX in vivo. The effect of B7-H4-ADC on cell cycle, DNA damage, and apoptosis was measured using flow cytometry. Results: B7-H4 is overexpressed in 92% of HGSOC tumors at diagnosis (n = 12), persisted in recurrent matched samples after platinum treatment, and was expressed at similar levels across metastatic sites after acquired multi-drug resistance (n = 4). Treatment with B7-H4-ADC resulted in target-specific growth inhibition of multiple ovarian and breast cancer cell lines. In platinum- or PARPi-resistant ovarian cancer cells, B7-H4-ADC significantly decreased viability and colony formation while increasing cell-cycle arrest and DNA damage, ultimately leading to apoptosis. Single-dose B7-H4-ADC led to tumor regression in 65.5% of breast and ovarian PDX models (n = 29), with reduced activity in B7-H4 low or negative models. In PARPi and platinum-resistant HGSOC PDX models, scheduled B7-H4-ADC dosing led to sustained tumor regression and increased survival. Conclusions: These data support B7-H4 as an attractive ADC target for treatment of drug-resistant HGSOC and provide evidence for activity of an ADC with a DNA-damaging payload in this population. See related commentary by Veneziani et al., p. 1434Keywords
All Related Versions
Funding Information
- National Center for Advancing Translational Sciences (TL1TR001880)
This publication has 48 references indexed in Scilit:
- Tisotumab Vedotin: First ApprovalDrugs, 2021
- Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mappingNeoplasia, 2021
- Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyLeukemia Research, 2020
- An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugatesRegulatory Toxicology and Pharmacology, 2019
- Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non–Small Cell Lung Carcinoma TumorsJournal of Thoracic Oncology, 2018
- T-cell target antigens across major gynecologic cancersGynecologic Oncology, 2017
- Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumorsGynecologic Oncology, 2017
- B7-H4 expression in ovarian serous carcinoma: a study of 306 casesHuman Pathology, 2016
- B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer lookGynecologic Oncology, 2014
- B7-H4 overexpression in ovarian tumorsGynecologic Oncology, 2006